Clinical Trial Goal
To find out if the combination of loncastuximab tesirine and rituximab before CAR T-cell therapy, is safe and works well to treat large B-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have large B-cell lymphoma that has relapsed or is refractory. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- High-grade B-cell lymphoma
- Primary mediastinal B-cell lymphoma (PMBCL)
- Transformed follicular lymphoma
- Are planning to have CD19-directed CAR T-cell therapy (your doctor can tell you this). Some examples include:
- Axi-cel
- Liso-cel
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a therapy that targets CD19. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 2 months
- Have not had an autologous (your own cells) BMT in the last 1 month
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Loncastuximab is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Loncastuximab tesirine – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Riktuximab – Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 15 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way before CAR T-cell therapy, to treat large B-cell lymphoma that has relapsed or is refractory is new and unproven.
Contacts
Rachel Kingsford, 801-585-0115, rachel.kingsford@hci.utah.edu
Narendranath Epperla, MD, MS, FACP, 801-585-0255, naren.epperla@hci.utah.edu
Locations
Huntsman Cancer Institute at University of UtahRECRUITING
Salt Lake City, Utah
Rachel Kingsford, 801-585-0115, rachel.kingsford@hci.utah.edu
Sponsors
collaborator: ADC Therapeutics S.A., lead: University of Utah
